Logo

Rani Therapeutics Holdings, Inc.

RANI

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendoc… read more

Healthcare

Biotechnology

4 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$1.51

Price

-0.66%

-$0.01

Market Cap

$110.219m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$1.200m

+16.7%

1y CAGR

+5.6%

3y CAGR

-20.8%

5y CAGR
Earnings

-$28.315m

+5.7%

1y CAGR

+2.1%

3y CAGR

-65.2%

5y CAGR
EPS

-$0.79

+24.8%

1y CAGR

+14.0%

3y CAGR

-40.7%

5y CAGR
Book Value

-$11.973m

$10.139m

Assets

$22.112m

Liabilities

$17.554m

Debt
Debt to Assets

173.1%

-0.4x

Debt to EBITDA
Free Cash Flow

-$27.782m

+22.3%

1y CAGR

+15.1%

3y CAGR

-0.5%

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases